Federal Register / Vol. 73, No. 44 / Wednesday, March 5, 2008 / Notices 11933 

Licensing Contact: Jasbir (Jesse) S. 

Kindra, J.D., M.S.; 301–435–5170; 

kindraj@mail.nih.gov. 

P53 and VGEF Regulate Tumor Growth 

of NO2 Expressing Cancer Cells 

Description of Technology: The 

increased expression of nitric oxide 

synthase 2 (NOS2), an inducible enzyme 

that produces nitric oxide (NO), has 

been found in a variety of human 

cancers. It also has been shown that 

NOS2-specific inhibitors can reduce the 

growth of experimental tumors in mice. 

These findings suggest a 

pathophysiological role for NO in the 

development and progression of cancer. 

However, the function of NO and NOS2 

in carcinogenesis is uncertain. NO had 

been found to either inhibit or stimulate 

tumor growth, and high concentrations 

of NO also are known to induce cell 

death in many cell types including 

tumor cells. On the other hand, low NO 

concentrations found in human tissue 

can have an opposite effect and protect 

against programmed cell death, or 

apoptosis, from various stimuli. The 

role of NO and NOS2 in tumor 

progression, particularly with respect to 

p53, therefore need to be further 

defined. 

This invention comprises methods of 

screening for modulators of NOS2 

expression in p53 mutant cells, both in 

vivo and in vitro, as well as methods for 

predicting the chemotherapeutic benefit 

of administering NOS2-inhibitors to 

cancer patients. It has been 

demonstrated that NOS2-expressing 

cancer cells with wild-type p53 have 

reduced tumor growth in athymic nude 

mice whereas NOS2-expressing cancer 

cells with mutated p53 have accelerated 

tumor growth. Therefore, this invention 

has potential application for a number 

of cancers that overexpress NOS2 and 

have a high frequency of p53 mutations, 

including breast, brain, head, neck, lung 

and colon cancers. 

Applications: 

Method to treat cancer with NOS2 

inhibitors. 

Method to screen for NOS2 

modulators. 

Method to predict therapeutic benefits 

of NOS2 inhibitors in patients. 

Market: 

An estimated 1,444,920 new cancer 

diagnoses in the U.S. in 2007. 

600,000 deaths caused by cancer in 

the U.S. in 2006. 

Cancer is the second leading cause of 

death in United States. 

It is estimated that market for cancer 

drugs would double to $50 billion a year 

in 2010 from $25 billion in 2006. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Stefan Ambs and Curt 

Harris (NCI). 

Publications: 

1. JE Goodman et al. Nitric oxide and 

p53 in cancer-prone chronic 

inflammation and oxyradical overload 

diseases. Environ Mol Mutagen. 

2004;44(1):3–9. 

2. LJ Hofseth et al. Nitric oxide in 

cancer and chemoprevention. Free 

Radic Biol Med. 2003Apr 15;34(8):955–

968. 

Patent Status: 

U.S. Patent Application No. 11/ 

195,006 filed 01 Aug 2005 (HHS 

Reference No. E–223–1998/0–US–04). 

U.S. Patent Application No. 09/ 

830,977 filed 02 May 2001 (HHS 

Reference No. E–223–1998/0–US–03). 

PCT Patent Application No. PCT/ 

US1999/27410 filed 17 Nov 1998 (HHS 

Reference No. E–223–1998/0–PCT–02). 

U.S. Provisional Patent Application 

No. 60/109,563 filed 23 Nov 1998 (HHS 

Reference No. E–223–1998/0–US–01). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Dated: February 26, 2008. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–4200 Filed 3–4–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflicts: Musculoskeletal Rehabilitation 

Sciences. 

Date: March 18, 2008. 

Time: 4 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: John P. Holden, PhD, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 4211, MSC 7814, Bethesda, MD 20892, 

301–496–8551, holdenjo@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Infectious 

Diseases Microbiology Fellowships. 

Date: March 19–20, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Alexander D. Politis, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3210, 

MSC 7808, Bethesda, MD 20892, 301–435–

1150, politisa@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Cancer Drug 

and Therapeutics Development SBIR/STTR. 

Date: March 20–21, 2008. 

Time: 9 a.m. to 8 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Steven B. Scholnick, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6152, 

MSC 7804, Bethesda, MD 20892, 301–435–

1719, scholnis@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflicts: Skeletal Muscle and Exercise 

Physiology. 

Date: March 20, 2008. 

Time: 3:30 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: John P. Holden, PhD, 

Center for Scientic Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 4211, MSC 7814, Bethesda, MD 20892, 

301–496–8551, holdenjo@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Developmental Pharmacology. 

Date: March 26, 2008. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 


jlentini on PROD1PC65 with NOTICES
11934 Federal Register / Vol. 73, No. 44 / Wednesday, March 5, 2008 / Notices 

Contact Person: Janet M. Larkin, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1102, 

MSC 7840, Bethesda, MD 20892, 301–435–

1026, larkinja@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Behavioral 

and Social HIV/AIDS Review of SBIR 

Applications. 

Date: March 28, 2008. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Mark P. Rubert, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892, 301–435–

1775, rubertm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Development of Assays for High Throughput 

Screening (HTS) in the Molecular Libraries 

Probe Production Centers Network (MLPCN). 

Date: April 3, 2008. 

Time: 8:30 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Georgetown Suites, 1000 29th Street, 

NW, Washington, DC 20007. 

Contact Person: George W. Chacko, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5170, 

MSC 7849, Bethesda, MD 20892, 301–435–

1245, chackoge@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 27, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–936 Filed 3–04–08; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Atherosclerotic and Lipid Metabolism. 

Date: March 11, 2008. 

Time: 1:30 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Anshumali Chaudhari, 

PhD, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4124, 

MSC 7802, Bethesda, MD 20892, (301) 435–

1210, chaudhaa@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.393–93.396, 93.337, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 27, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–937 Filed 3–4–08; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, Mentored Career 

Development Award Review Meeting. 

Date: April 7, 2008. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NIEHS/National Institutes of Health, 

Building 4401, East Campus, 79 T.W. 

Alexander Drive, Research Triangle Park, NC 

27709, (Telephone Conference Call). 

Contact Person: Linda K. Bass, Scientific 

Review Administrator, Scientific Review 

Branch, Division of Extramural Research and 

Training, Nat. Institute Environmental Health 

Sciences, P.O. Box 12233, MD EC–30, 

Research Triangle Park, NC 27709, (919) 541–

1307, bass@niehs.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: February 27, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–938 Filed 3–4–08; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases: Licensing 

Opportunity and Cooperative Research 

and Development Agreement 

(‘‘CRADA’’) Opportunity; Live 

Attenuated Vaccine To Prevent 

Disease Caused by West Nile Virus 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The National Institute of 

Allergy and Infectious Diseases (NIAID) 

of the NIH is seeking licensees and/or 

CRADA partners to further develop, 

evaluate, and commercialize modified 

West Nile virus (WNV) chimeras as a 

live attenuated vaccine against 

infections of WNV in humans. NIAID is 

also seeking licensees to commercialize 

modified WNV chimeras as live 

attenuated veterinary vaccines against 

infections of WNV in animals. 

DATES: Respondents interested in 

licensing the invention will be required 

to submit an ‘‘Application for License to 

Public Health Service Inventions’’ on or 


jlentini on PROD1PC65 with NOTICES